What changed the interpretation of the GRIA3 splice-site variant?

The reported reclassification could reflect direct evidence that the variant alters GRIA3 splicing, or a stronger clinical-genetic argument based on segregation and phenotype without functional confirmation. Those explanations carry different mechanistic weight.

The key distinction is whether patient-derived RNA or another assay identified an abnormal transcript and quantified residual normal splicing. If reclassification instead rested mainly on cosegregation, the family’s X-linked pattern, variant rarity, and alternative candidate variants become especially important. Phenotypic differences by sex and X-inactivation data could further test whether variable GRIA3 dosage explains the intellectual disability and psychiatric features.